276 361

Cited 0 times in

췌장암의 항암치료와 방사선 치료 최신 지견

Other Titles
 Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer 
 성민제  ;  방승민 
 Korean Journal of Pancreas and Biliary Tract (대한췌담도학회지), Vol.25(2) : 72-82, 2020-07 
Journal Title
Korean Journal of Pancreas and Biliary Tract(대한췌담도학회지)
Issue Date
Pancreatic cancer ; Pancreatic adenocarcinoma ; Chemotherapy ; Radiotherapy
Pancreatic cancer is still one of the most aggressive malignancy, showing 10% of 5-year survival. Among the several reasons of the grave prognosis, the poor response to chemotherapeutic agents and the absence of effective tool for early detection are the most important. Regarding treatments, surgical resection is still positioned as the only one for expecting the cure of pancreatic cancer. However, the rate of recurrence after surgery is still high as more than 50%. And the portion of patients who are diagnosed at the resectable stage is still less than 15% of all cases. So, chemotherapy and radiotherapy are the main players for combating with pancreatic cancer. After the introduction of outcomes of FOLFIRINOX, and gemcitabine/nabpaclitaxel for metastatic pancreatic cancer, two-digit overall survival can be expected. And, neoadjuvant treatments including concurrent chemoradiation therapy for borderline resectable pancreatic cancer and/or resectable pancreatic cancer are reported as superior to upfront surgery. More recently, several target agents including polyadenosine diphosphate-ribose polymerase inhibitors and immunologic drugs are under evaluation for pancreatic cancer. So, herein, current status of chemotherapy and radiation therapy for pancreatic cancer will be addressed.
Files in This Item:
T999202338.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Sung, Min Je(성민제) ORCID logo https://orcid.org/0000-0001-5395-8851
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.